Clinical Genomics Implements QIAGEN’s Tube Collection Technology for Colorectal Cancer Recurrence Assay
On August 21, Clinical Genomics announced they have implemented QIAGEN’s PAXgene circulating cell-free DNA tube blood sample collection in its Colvera colorectal cancer recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician’s office.
The PAXgene System will enable physicians to provide recurrence assay testing more conveniently than with alternative sample collection methods. PAXgene allows a simple blood collection at the physician’s office with no onsite processing required.
Clinical Genomics and QIAGEN have demonstrated that PAXgene circulating, cell-free DNA yield and Colvera assay performance is equivalent to the performance from blood samples collected in ethylenediaminetetraacetic acid tubes, spun down to plasma and frozen within 8 hours of collection. The PAXgene process demonstrated a significantly superior ease of use and robustness.
These findings will be presented in a poster at the Association for Molecular Pathology (AMP) 2017 Annual Meeting in November in Salt Lake City.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
